Antitrust, Commercial, and Administrative Law

Washington, D.C. – House Judiciary Committee Chairman Bob Goodlatte (R-Va.), House Financial Services Committee Chairman Jeb Hensarling (R-Tx.), Regulatory Reform, Commercial and Antitrust Law Subcommittee Chairman Tom Marino (R-Pa.), Financial Institutions and Consumer Credit Subcommittee Chairman Blaine Luetkemeyer (R-Mo.), and Courts, Intellectual Property & the Internet Subcommittee Chairman Darrell Issa (R-Ca.) sent a letter to Attorney General Jeff Sessions, Federal Reserve Board Chair Janet Yellen, and Acting Comptroller Keith Noreika regarding Operation Choke Point. The Obama Administration initiated Operation Choke Point to discourage financial institutions from offering services

Washington, D.C. - This week, leaders of both the Senate and House Judiciary Committees called on the Justice Department and Federal Trade Commission to work with the U.S. Trade Representative to make strong competition provisions a central part of upcoming trade negotiations.

Chairman Goodlatte: The United States has been and continues to be a champion of free and open markets. An open marketplace cultivates competition among sellers and is the very foundation of maintaining lower prices, higher quality products and services, and superior innovation. The antitrust laws established in this country serve a valuable role in promoting competition, and the Judiciary Committee routinely exercises its oversight authority to ensure that these laws are applied in a manner that is transparent, fair, predictable, and reasonably stable over time. One area of essential antitrust oversight is the health care industry.

Washington, D.C. -- On Thursday, July 27, 2017 at 1:00 p.m., the Regulatory Reform, Commercial and Antitrust Law Subcommittee will hold a hearing to examine antitrust concerns with the Food and Drug Administration processes to approve new drugs. This hearing will continue the Subcommittee’s investigation of competition in the healthcare sector and will explore potential antitrust concerns with the FDA’s Risk Evaluation and Mitigation Strategy (REMS), citizen petitions, the Unapproved Drug Initiative, and “Pay-for-Delay” settlements. The witnesses for the hearing include: Panel I:

Washington, D.C. – House Judiciary Committee Chairman Bob Goodlatte (R-Va.) today delivered the following remarks during the Regulatory Reform, Commercial and Antitrust Law Subcommittee’s hearing on “No Regulation Without Representation:  H.R.

Washington, D.C. -- On Tuesday, July 25, 2017 at 10:00 a.m., the Subcommittee on Regulatory Reform, Commercial and Antitrust Law Subcommittee will hold a hearing on the growing problem of states imposing regulatory burdens on out-of-state businesses and the No Regulation without Representation Act of 2017 (H.R. 2887), which addresses the problem. The witnesses for the hearing are:

• Mr.

Washington, D.C. -- Today regulatory experts from across the country sent a letter to Senate Majority Leader Mitch McConnell (R-KY) and Minority Leader Chuck Schumer (D-NY) urging them to enact comprehensive regulatory reform.